股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 閩信集團有限公司 | | | | 呈交日期: | 2026年1月2日 | | | | I. 法定/註冊股本變動 | 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00222 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 597,257,252 | | 0 | | 597,257,252 | | 增加 / 減少 (-) | | ...

Core Viewpoint - Minxin Group (00222) has entered into a loan agreement with a bank, securing a non-committed revolving credit facility of up to HKD 390 million, effective December 11, 2025 [1] Group 1: Loan Agreement Details - The bank has the discretion to modify, cancel, or suspend the credit facility without prior notice, including the cancellation of any unused credit [1] - The bank can also change, modify, or supplement any terms of the loan agreement at its discretion, which may lead to the immediate termination of the credit facility if the company disagrees [1] - Any outstanding amounts under the credit facility will become immediately due and payable if the company does not agree to the changes [1]

Group 1 - The company, Minxin Group (00222), has entered into a loan agreement with a bank, providing a non-committed revolving credit facility of up to HKD 390 million [1] - The bank retains the right to modify, cancel, or suspend the credit facility at its discretion without prior notice, including the cancellation of any unused credit [1] - If the company disagrees with any changes made by the bank to the loan agreement, the credit facility will be immediately terminated, and all outstanding amounts will become due [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 按上市規則第 13.18 條規定作出之公告 本公告乃由閩信集團有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》（「《上市規 則》」）第13.18條項下的披露規定 而作出。 於2025年12月11日，本公司作為借款人與一間銀行（「銀行」）作為貸 款人簽訂一份貸款協議（「貸款協議」），銀行同意向本公司提供上限 為港幣390,000,000元的非承諾性循環授信額度（「授信 額度」）。銀行 可隨時在不經事先通知的情況下全權酌情修改、取消或暫停授信額度， 包括 但不限於 取消任 何未動 用 的 授信及 宣佈任 何 未償 還 款 項即 時到期 及償 還。銀行 亦可全 權酌情 通 過 向本公 司發出 通 知變 更 、 ...

Core Viewpoint - The stock price of Tailong Pharmaceutical (600222) experienced significant volatility after the announcement of a potential change in ownership, initially rising to the limit but then plummeting to a drop limit, ultimately closing down 4.43% on the day of resumption of trading [1][4]. Group 1: Ownership Change - Tailong Pharmaceutical's controlling shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd. (Tairong Investment), is planning to transfer shares, which may lead to a change in control of the company [3][6]. - Tairong Investment intends to transfer 50.1 million shares to Jiang Pharmaceutical Group Jiangxi Medical Holdings Co., Ltd. (Jiang Pharmaceutical Holdings) at a price of 11.043 CNY per share, representing a premium of over 28% compared to the pre-suspension price of 8.58 CNY per share [3][6]. - Following the completion of the transaction, the controlling shareholder will change from Tairong Investment to Jiang Pharmaceutical Holdings, and the actual controller will shift from the Zhengzhou High-tech Industrial Development Zone Management Committee to the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [3][6]. Group 2: Financial Performance - During Tairong Investment's tenure, Tailong Pharmaceutical's performance has been inconsistent, with a revenue increase of 22.2% in 2022, the highest growth since 2018, but a net profit loss [7]. - In the first three quarters of 2024, Tailong Pharmaceutical's revenue declined to 1.187 billion CNY, a year-on-year decrease of 11.47%, and the net profit attributable to shareholders was 25 million CNY, down 12.36% year-on-year [4][7].

Group 1 - The core point of the news is that Tai Long Pharmaceutical experienced significant stock price volatility, opening with a limit increase before dropping sharply and then recovering slightly by the end of the trading day [1] - After a week of suspension, Tai Long Pharmaceutical announced that its controlling shareholder, Tai Rong Investment, had reached an agreement with relevant parties regarding a potential change in company control, leading to the resumption of trading on December 9 [3] - On December 8, Tai Rong Investment and Zhengzhou Zhongsheng Industrial Group, a shareholder with over 5% stake, reached an agreement with Jiang Pharmaceutical Holdings regarding a share transfer and governance matters, which includes the transfer of 8.73% of the company's shares at a price of 11.043 yuan per share, totaling 553 million yuan [4] Group 2 - The agreement will establish a consistent action relationship between Tai Rong Investment and Jiang Pharmaceutical Holdings regarding major company decisions, solidifying Jiang Pharmaceutical Holdings' control over Tai Long Pharmaceutical [4] - If the share transfer and related agreements proceed smoothly, Jiang Pharmaceutical Holdings will hold 7.37% of the shares after the first transfer, and through the agreement, will control a total of 14.37% of the shares, resulting in a change of the controlling shareholder from Tai Rong Investment to Jiang Pharmaceutical Holdings [4]

Market Overview - Major indices opened lower but quickly rebounded, with the ChiNext Index and STAR Market 50 Index turning positive [1] - CPO concept stocks continued to perform strongly, with Zhongci Electronics hitting the daily limit, and Shaanxi Huada and Dekeli rising over 10% [1] - Innovative drug concept stocks gained traction, with Haichuang Pharmaceutical-U rising over 14%, and Zhaoyan New Drug, Peking University Pharmaceutical, and Chengdu Xian Dao increasing over 5% [1] - The shipbuilding sector saw broad gains, with China Shipbuilding and China Power rising over 3% [1] - Film and cinema stocks were active, with Ciweng Media and Bona Film Group rising over 6%, followed by Huace Film and China Film [1] New Stock Offering - Yuanchuang Co., Ltd. opened for subscription today, issuing a total of 19.6 million shares at a price of 24.75 yuan, with an earnings per share ratio of 12.93 times [1] - The company specializes in the research, production, and sales of rubber track products, primarily used in agricultural and engineering machinery [1] - Yuanchuang holds the top market share in the domestic rubber track industry according to recent reports [1] Private Placement Announcements - Three companies announced private placement plans on December 9, with Purun Co., Ltd. seeing a significant price increase after resuming trading [2] - Tailong Pharmaceutical plans to issue up to 74.61 million shares at 6.09 yuan each, aiming to raise 454 million yuan for working capital and debt repayment [2] - Following a share transfer agreement, Tailong's controlling shareholder will change to Jiang Pharmaceutical Holdings, with the actual controller becoming the Jiangxi State-owned Assets Supervision and Administration Commission [2] Mergers and Acquisitions - Purun Co., Ltd. plans to acquire 49% of Noah Changtian's equity through a combination of share issuance, convertible bonds, and cash [3] - Yongda Co., Ltd. intends to purchase 49% of Jinyuan Equipment's equity from Ge Yanming, with plans to issue shares to specific investors for funding [3] Financing Activities - As of December 8, the market's financing balance reached 2.48 trillion yuan, an increase of 186.32 billion yuan from the previous trading day [4] - A total of 617 stocks saw net financing purchases exceeding 10 million yuan, with 49 stocks exceeding 100 million yuan [4] - Shenghong Technology topped the list with a net purchase of 1.254 billion yuan, followed by Tianfu Communication and Xiangshang Chip Creation [4] Sector Analysis - In the sector analysis, electronics, non-ferrous metals, and non-bank financials were prominent among stocks with net purchases exceeding 100 million yuan [5] - The average financing balance as a percentage of market capitalization was 4.67%, with C Moer-U having the highest ratio at 11.35% [5] - Other stocks with high financing balance ratios included Jianqiao Technology, Zhishang Technology, and Dongfang Caifu [5]

Market Overview - Major indices opened lower but quickly rebounded, with the ChiNext Index and the Sci-Tech 50 Index turning positive [1] Sector Performance - CPO concept stocks continued to perform strongly, with Zhongci Electronics hitting the daily limit, and Shaanxi Huada and Dekeli rising over 10% [2] - The innovative drug sector saw gains, with Haichuang Pharmaceutical-U increasing over 14%, and Zhaoyan New Drug, Peking University Pharmaceutical, and Chengdu XianDao rising over 5% [3] - The shipbuilding sector experienced broad gains, with China Shipbuilding and China Power both rising over 3% [4] - Film and cinema stocks were active, with Ciweng Media and Bona Film Group rising over 6%, followed by Huace Film and China Film [5] New Stock Offerings - Yuanchuang Co., Ltd. opened for subscription today, issuing a total of 19.6 million shares at a price of 24.75 yuan, with an earnings per share ratio of 12.93 [6] - The company specializes in the research, production, and sales of rubber track products, holding the top domestic market share according to recent reports [7] Private Placement Announcements - Three companies announced private placement plans, with Purun Co., Ltd. seeing a significant rise of over 17% after resuming trading [8] - Tailong Pharmaceutical plans to issue up to 74.6 million shares at 6.09 yuan each, raising approximately 454 million yuan for working capital and debt repayment [8] Financing Activities - As of December 8, the market's financing balance reached 2.48 trillion yuan, an increase of 186.32 billion yuan from the previous trading day [10] - A total of 49 stocks saw net purchases exceeding 100 million yuan, with Shenghong Technology leading at 1.254 billion yuan [10] - The electronics, non-ferrous metals, and non-bank financial sectors saw significant net purchases, with 18, 5, and 5 stocks respectively [11]

Core Viewpoint - The potential new controlling shareholder of Tai Long Pharmaceutical has emerged, with Jiang Pharmaceutical Group acquiring an 8.73% stake through a share transfer agreement, marking a significant shift in company control [2][5][6]. Group 1: Share Transfer and Control Change - Tai Long Pharmaceutical announced that its controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., and other major shareholders have reached an agreement with Jiang Pharmaceutical Group for a share transfer [2]. - Jiang Pharmaceutical Group will acquire 50.1 million shares at a price of 11.043 yuan per share, totaling approximately 553 million yuan [6]. - Following the transaction, Jiang Pharmaceutical Group will hold 124.7 million shares, representing 19.23% of the total share capital, thus becoming the new controlling shareholder [5][8]. Group 2: Financial Details and Future Plans - The share transfer involves a combination of "agreement transfer + concerted action arrangement + private placement," with Jiang Pharmaceutical Group also planning to invest up to 454 million yuan in a private placement to further solidify its control [6][7]. - The private placement will involve issuing up to 74.6 million shares at a price of 6.09 yuan per share, aimed at enhancing the company's liquidity and reducing debt [7]. Group 3: Strategic Implications - Jiang Pharmaceutical Group aims to leverage its resources and brand advantages to enhance Tai Long Pharmaceutical's operational capabilities and market position [9][10]. - Tai Long Pharmaceutical specializes in drug manufacturing and R&D services, with a product portfolio that includes various traditional Chinese medicine formulations [10]. - The partnership is expected to facilitate the integration of resources and promote high-quality development within the pharmaceutical industry [10].

Group 1 - The controlling shareholder of Tailong Pharmaceutical is planning to transfer shares, which may lead to a change in company control. The company's stock will be suspended from trading starting December 2 [1][3][6] - The suspension of trading is expected to last no more than two trading days, during which the company will comply with information disclosure obligations as per legal regulations [3][6] - As of the end of the third quarter, the controlling shareholder, Zhengzhou TaiRong Industrial Investment Co., holds 82,441,168 shares, accounting for 14.37% of the total shares [8][9] Group 2 - For the first three quarters of the year, Tailong Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [11][12] - The company's main business includes drug manufacturing and research services, covering four segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [8]